Ginger as a Modifier of Ghrelin Levels in Parkinson’s Disease and REM Sleep Behavior Disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an experimental medicine study to see if ginger supplementation can increase blood ghrelin levels in three groups: people with Parkinson’s disease, people with REM sleep behavior disorder, and age- and sex-mimicked healthy controls. Participants are randomized to one of two ginger dose levels (0.24 g or 0.48 g of ginger root extract) taken daily for 12 weeks, with up to four visits and optional home visits. The primary aim is to determine a dose-related change in ghrelin; secondary aims include effects on inflammation, gut symptoms such as constipation, and tolerability in Parkinson’s patients. The study is conducted at the University of Cambridge with Cambridge University Hospitals NHS Foundation Trust as the lead sponsor and Swansea University as a collaborator.

Why it matters

Who can join: the full rules

People with PD

* 55 years of age or above;
* Meet Movement Disorder Society criteria for Idiopathic PD

People with RBD

* 55 years of age or above;
* RBD diagnosis confirmed by polysomnography;
* Prodromal PD probability score of 80% or above on the Movement Disorders Society calculator.

Controls

• 55 years of age or above.

Where it's running

• University of Cambridge
  Cambridge, United Kingdom Recruiting

Study contacts

• Principal investigator: Caroline H. Williams-Gray, BMBCh FRCP PhD — University of Cambridge
• Study coordinator: Marta Camacho, PhD
• Email: msc72@medschl.cam.ac.uk
• Phone: 00441223334121

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• Intraoperative Microelectrode Recordings with MAVEN vs Standard Equipment

  This study tests whether MAVEN can match the recording data collected during DBS surgery for movement disorders using standard equipment.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07868614

• Mental imagery with self-regulation to help daily activities in Parkinson's disease

  This study tests whether a six-week program of mental imagery combined with self-regulation can help people with Parkinson’s perform daily activities better than standard learning or exercise.

  Recruiting The Hong Kong Polytechnic University · Hong Kong · NCT07860294

• Real-world experiences of Inbrija for Parkinson's OFF episodes

  This study looks at how people with Parkinson’s who use Inbrija for OFF episodes feel and function in daily life.

  Recruiting Merz Pharmaceuticals GmbH · Altmünster and 1 other locations · NCT07797790

• Early PD signals in people with REM sleep behavior disorder

  This study tests whether people with REM sleep behavior disorder show early signs of Parkinson’s disease before classic symptoms appear.

  Recruiting Danish Research Centre for Magnetic Resonance · Hvidovre · NCT07790744

• Test of RO7568282 in early Parkinson's disease

  This study tests whether RO7568282, compared with placebo, is safe and helps people with early Parkinson's disease who are already taking levodopa.

  Recruiting at 4 sites Phase 2 Hoffmann-La Roche · Boca Raton, Florida and 3 other locations · NCT07781644

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.